Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Child's Nervous System

13-04-2024 | Glioma | Review

Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature

Authors: Jordan T. Roach, Cecile Riviere-Cazaux, Brennan A. Wells, Frederick A. Boop, David J. Daniels

Published in: Child's Nervous System

Login to get access

Abstract

Purpose

Pediatric-type diffuse high-grade gliomas are the leading cause of cancer-related morbidity and mortality in children. More than 30% of diffuse hemispheric gliomas (DHG) in adolescents harbor histone H3 G34 mutations and are recognized by the World Health Organization as a distinct tumor entity. By reporting bibliometric characteristics of the most cited publications on H3 G34-mutant DHG (H3 G34 DHG), we provide an overview of emerging literature and speculate where future research efforts may lead.

Methods

One hundred fourteen publications discussing H3 G34 DHG were identified, categorized as basic science (BSc), clinical (CL), or review (R), and ranked by citation number. Various bibliometric parameters were summarized, and a comparison between article types was performed.

Results

Articles within this study represent principal investigators from 15 countries and were published across 63 journals between 2012 and 2024, with 36.84% of articles originating in the United States. Overall median values were as follows: citation count, 20 (range, 0–2591), number of authors, 9 (range, 2–78), and year of publication, 2020 (range, 2012–2024). Among the top ten most cited articles, BSc articles accounted for all ten reports. Compared to CL and R articles, BSc articles were published in journals with higher impact factors.

Conclusion

We establish variability in bibliometric parameters for the most cited publications on H3 G34 DHG. Our findings demonstrate a paucity of high-impact and highly cited CL reports and acknowledge an unmet need to intersect basic mechanism with clinical data to inform novel therapeutic approaches.
Appendix
Available only for authorised users
Literature
1.
Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G et al (2022) CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol 24((Suppl 3)):iii1–iii38CrossRefPubMedPubMedCentral
2.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64(2):83–103CrossRefPubMed
3.
Schwartzentruber, Korshunov J, Liu A, Jones XY, Pfaff DT, Jacob E et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–31CrossRefPubMed
4.
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437CrossRefPubMed
5.
Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253CrossRefPubMedPubMedCentral
6.
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 34(4):520–37 e5CrossRef
7.
Chen CCL, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade AF et al (2020) Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis. Cell 183(6):1617–33 e22CrossRefPubMedPubMedCentral
8.
Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131(1):137–146CrossRefPubMed
9.
Ocasio JK, Budd KM, Roach JT, Andrews JM, Baker SJ (2023) Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma. Cancer Metastasis Rev 42(2):367–388CrossRefPubMed
10.
Funato K, Smith RC, Saito Y, Tabar V (2021) Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma. Cell Stem Cell 28(5):894-905 e7CrossRefPubMedPubMedCentral
11.
Bressan RB, Southgate B, Ferguson KM, Blin C, Grant V, Alfazema N et al (2021) Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants. Cell Stem Cell 28(5):877–93 e9CrossRefPubMedPubMedCentral
12.
Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340(6134):857–861CrossRefPubMedPubMedCentral
13.
Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669–678CrossRefPubMed
14.
Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S et al (2013) Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3(5):512–9CrossRefPubMedPubMedCentral
15.
Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J et al (2018) Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell 33(5):829–42 e5CrossRefPubMedPubMedCentral
16.
Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Muhleisen H, Eckert F et al (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4(1):60CrossRefPubMedPubMedCentral
17.
Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Canete A et al (2018) Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 36(10):951–958CrossRefPubMed
18.
Hwang EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S et al (2018) Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children’s Oncology Group Randomized ACNS0332 Trial. J Clin Oncol 36(34):JCO2017764720CrossRefPubMed
19.
Gessi M, Gielen GH, Hammes J, Dorner E, Muhlen AZ, Waha A et al (2013) H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 112(1):67–72CrossRefPubMed
20.
Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y et al (2017) Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34(3):103–12CrossRefPubMed
21.
Roux A, Pallud J, Saffroy R, Edjlali-Goujon M, Debily MA, Boddaert N et al (2020) High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro Oncol 22(8):1190–1202CrossRefPubMedPubMedCentral
22.
Lowe BR, Maxham LA, Hamey JJ, Wilkins MR, Partridge JF (2019) Histone H3 mutations: an updated view of their role in chromatin deregulation and cancer. Cancers (Basel) 11(5)
23.
24.
Fontebasso AM, Liu XY, Sturm D, Jabado N (2013) Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol 23(2):210–216CrossRefPubMedPubMedCentral
25.
Wood MD, Halfpenny AM, Moore SR (2019) Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol 14(1):29CrossRefPubMedPubMedCentral
26.
Vanan MI, Eisenstat DD (2014) Management of high-grade gliomas in the pediatric patient: past, present, and future. Neurooncol Pract 1(4):145–157PubMedPubMedCentral
27.
Salloum R, McConechy MK, Mikael LG, Fuller C, Drissi R, DeWire M et al (2017) Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathol Commun 5(1):78CrossRefPubMedPubMedCentral
28.
Gerges N, Fontebasso AM, Albrecht S, Faury D, Jabado N (2013) Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Med 5(7):66CrossRefPubMedPubMedCentral
29.
Khazaei S, Chen CCL, Andrade AF, Kabir N, Azarafshar P, Morcos SM et al (2023) Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration. Cell 186(6):1162–78 e20CrossRefPubMedPubMedCentral
30.
Andrade AF, Chen CCL, Jabado N (2023) Oncohistones in brain tumors: the soil and seed. Trends Cancer 9(5):444–455CrossRefPubMed
31.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251CrossRefPubMedPubMedCentral
32.
Fang J, Huang Y, Mao G, Yang S, Rennert G, Gu L et al (2018) Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSalpha interaction. Proc Natl Acad Sci U S A 115(38):9598–9603CrossRefPubMedPubMedCentral
33.
Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S et al (2016) A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neurooncol 127(1):53–61CrossRefPubMed
34.
Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA et al (2020) Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience. J Neurooncol 148(3):607–617CrossRefPubMed
35.
Rodriguez Gutierrez D, Jones C, Varlet P, Mackay A, Warren D, Warmuth-Metz M et al (2020) Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY Phase II Trial. Clin Cancer Res 26(8):1856–1865CrossRefPubMed
36.
Khan NR, Thompson CJ, Taylor DR, Gabrick KS, Choudhri AF, Boop FR et al (2013) Part II: should the h-index be modified? An analysis of the m-quotient, contemporary h-index, authorship value, and impact factor. World Neurosurg 80(6):766–774CrossRefPubMed
37.
Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P et al (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45(12):1479–1482CrossRefPubMed
38.
Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A et al (2013) Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 125(5):659–669CrossRefPubMedPubMedCentral
Metadata
Title
Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature
Authors
Jordan T. Roach
Cecile Riviere-Cazaux
Brennan A. Wells
Frederick A. Boop
David J. Daniels
Publication date
13-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-024-06395-8